Evidence map›Paper›PMID 30951568›Full record

ArticleJournal of hepatocellular carcinoma2019

Road map for fibrolamellar carcinoma: progress and goals of a diversified approach.

Edward R Kastenhuber, John Craig, Jon Ramsey, Kevin M Sullivan, Julien Sage, Sofia de Oliveira, Kimberly J Riehle, John D Scott, John D Gordan, Nabeel Bardeesy and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Edward R KastenhuberCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, abou-alg@mskcc.org.
John CraigFibrolamellar Cancer Foundation, Greenwich, CT, USA.
Jon RamseyDepartment of Biochemistry, University of Vermont Cancer Center, Burlington, VT, USA.
Kevin M SullivanNorthwest Liver Research Program, University of Washington, Seattle, WA, USA.
Julien SageDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Sofia de OliveiraDepartment of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI, USA.
Kimberly J RiehleNorthwest Liver Research Program, University of Washington, Seattle, WA, USA.
John D ScottNorthwest Liver Research Program, University of Washington, Seattle, WA, USA.
John D GordanDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Nabeel BardeesyCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Ghassan K Abou-AlfaCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, abou-alg@mskcc.org.
University of Washington · USMemorial Sloan Kettering Cancer Center · USFibrolamellar Cancer Foundation · USHarvard University · USStanford University · USUniversity of California, San Francisco · USUniversity of Vermont · USUniversity of Wisconsin–Madison · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Neurotensin in Fibrolamellar Liver CancerR21CA201867 · NCI · UNIVERSITY OF WASHINGTON · PI RIEHLE, KIMBERLY J · 2016 to 2017
$370k
Intratumoral Heterogeneity and Tumor Evolution in LymphomaF31CA192835 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KASTENHUBER, EDWARD R · 2015 to 2018
$157k
NCI NIH HHS F31 CA192835NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA201867
6 · The paper itself

Abstract

Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner.

Indexed as

adolescentcyclic AMP-dependent protein kinase catalytic subunitfibrolamellar carcinomafusion oncogeneheat shock protein 40liver canceryoung adult

Identifiers

PMID30951568
PMCPMC6362920
OpenAlexW2913313778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.